ZA200203704B - Pharmaceutical formulations containing zolmitriptan. - Google Patents

Pharmaceutical formulations containing zolmitriptan.

Info

Publication number: ZA200203704B
Authority: ZA; South Africa
Prior art keywords: pharmaceutical formulations; formulations containing; zolmitriptan; containing zolmitriptan; formulation
Prior art date: 1999-12-03

Application number

ZA200203704A

Other languages

English (en)

Inventor

Alan Roy Dearn

Simon John Summers

Sarah Louise Williamson

Trevor John Coomber

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-03

Filing date

2002-05-09

Publication date

2003-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200203704(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-05-09 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-10-29 Publication of ZA200203704B publication Critical patent/ZA200203704B/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 title abstract 2
229960001360 zolmitriptan Drugs 0.000 title abstract 2
208000019695 Migraine disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

ZA200203704A 1999-12-03 2002-05-09 Pharmaceutical formulations containing zolmitriptan. ZA200203704B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9928578.5A GB9928578D0 (en)	1999-12-03	1999-12-03	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
ZA200203704B true ZA200203704B (en)	2003-10-29

Family

ID=10865629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200203704A ZA200203704B (en)	1999-12-03	2002-05-09	Pharmaceutical formulations containing zolmitriptan.

Country Status (28)

Country	Link
US (2)	US6750237B1 (de)
EP (1)	EP1237551B1 (de)
JP (1)	JP2003515559A (de)
KR (1)	KR100670092B1 (de)
CN (1)	CN1222287C (de)
AT (1)	ATE291914T1 (de)
AU (1)	AU778092B2 (de)
BR (1)	BRPI0016138B8 (de)
CA (1)	CA2392050C (de)
CZ (1)	CZ301528B6 (de)
DE (1)	DE60019162T2 (de)
EE (1)	EE05305B1 (de)
ES (1)	ES2236001T3 (de)
GB (2)	GB9928578D0 (de)
HK (2)	HK1048445B (de)
HU (1)	HU229458B1 (de)
IL (2)	IL149578A0 (de)
IS (1)	IS2135B (de)
MX (1)	MXPA02005319A (de)
NO (1)	NO322119B1 (de)
NZ (1)	NZ518862A (de)
PL (1)	PL200679B1 (de)
PT (1)	PT1237551E (de)
RU (1)	RU2255736C2 (de)
SK (1)	SK287228B6 (de)
UA (1)	UA75059C2 (de)
WO (1)	WO2001039772A1 (de)
ZA (1)	ZA200203704B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8465468B1 (en)	2000-06-29	2013-06-18	Becton, Dickinson And Company	Intradermal delivery of substances
GB9928578D0 (en) *	1999-12-03	2000-02-02	Zeneca Ltd	Pharmaceutical formulations
SE0102855D0 (sv) *	2001-08-27	2001-08-27	Astrazeneca Ab	Method of treatment
EP1744784A2 (de) *	2004-05-11	2007-01-24	Becton, Dickinson and Company	Schmerzmittelformulierungen und verfahren zu deren anwendung
US8216610B2 (en)	2004-05-28	2012-07-10	Imaginot Pty Ltd.	Oral paracetamol formulations
EP3216445A1 (de) *	2004-05-28	2017-09-13	Imaginot Pty Ltd.	Abgabesystem für eine orale therapeutische verbindung
EP1812428A2 (de) *	2004-11-19	2007-08-01	Teva Pharmaceutical Industries Ltd	Zolmitriptan-kristallformen
CN100341504C (zh) *	2004-12-01	2007-10-10	鲁南制药集团股份有限公司	佐米曲普坦速释制剂
CA2629904C (en) *	2005-11-28	2018-07-10	Imaginot Pty Ltd.	Oral therapeutic compound delivery system
US20100048609A1 (en) *	2006-08-01	2010-02-25	Jacobs Jeffrey W	Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
CA2666149A1 (en) *	2006-10-19	2008-04-24	Auspex Pharmaceuticals, Inc.	Substituted indoles
KR101517415B1 (ko) *	2008-05-14	2015-05-07	에스케이바이오팜 주식회사	난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
SI2627328T1 (sl)	2010-10-15	2017-01-31	Contera Pharma Aps	Kombinacije agonistov receptorjev serotonina za zdravljenje motenj premikanja
JP6121734B2 (ja) *	2012-02-09	2017-04-26	久光製薬株式会社	マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
CN104411301B (zh)	2012-04-18	2018-02-06	康特拉医药公司	适于改善运动障碍治疗的口服药物配方
US11554229B2 (en)	2013-03-26	2023-01-17	OptiNose Inc.	Nasal administration
KR101624049B1 (ko)	2014-10-29	2016-05-24	연세대학교 산학협력단	사카린을 이용한 용해도를 증가시킨 약제학적 조성물
EP3310360B1 (de) *	2015-06-19	2024-03-27	Beijing Artivila BioPharma Co. Ltd.	Chirale spezifische borhaltige verbindungen und deren verwendung in der behandlung von krebs oder amyloidose
WO2017122161A1 (en)	2016-01-15	2017-07-20	Cadila Healthcare Limited	An intranasal composition comprising 5ht1b/1d receptor agonists
AU2017297718B2 (en)	2016-07-11	2023-06-08	Contera Pharma A/S	Pulsatile drug delivery system for treating morning akinesia
EP3727333A1 (de) *	2017-12-21	2020-10-28	Taiwan Liposome Company Ltd	Triptanzusammensetzungen mit verzögerter freisetzung und verfahren zur herstellung davon auf subdermalem weg oder dergleichen
US20210322343A1 (en)	2020-04-15	2021-10-21	Farzana Shaheen	Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT97888B (pt) *	1990-06-07	1998-12-31	Zeneca Ltd	Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
GB9012672D0 (en) *	1990-06-07	1990-08-01	Wellcome Found	Therapeutic heterocyclic compounds
GB9516145D0 (en) *	1995-08-07	1995-10-04	Wellcome Found	Improved chemical synthesis
WO1998002186A1 (en) *	1996-07-11	1998-01-22	Farmarc Nederland B.V.	Inclusion complex containing indole selective serotonin agonist
GB2315673A (en) *	1996-08-01	1998-02-11	Merck & Co Inc	Treatment of migraine
JP2001511160A (ja) *	1997-02-05	2001-08-07	ヤゴリサーチアクチェンゲゼルシャフト	医学用エアゾール配合物
GB9928578D0 (en) *	1999-12-03	2000-02-02	Zeneca Ltd	Pharmaceutical formulations

1999
- 1999-12-03 GB GBGB9928578.5A patent/GB9928578D0/en not_active Ceased
2000
- 2000-11-28 BR BRPI0016138A patent/BRPI0016138B8/pt not_active IP Right Cessation
- 2000-11-28 CN CNB008163820A patent/CN1222287C/zh not_active Expired - Lifetime
- 2000-11-28 KR KR1020027006849A patent/KR100670092B1/ko not_active Expired - Lifetime
- 2000-11-28 JP JP2001541504A patent/JP2003515559A/ja active Pending
- 2000-11-28 SK SK753-2002A patent/SK287228B6/sk not_active IP Right Cessation
- 2000-11-28 PT PT00979765T patent/PT1237551E/pt unknown
- 2000-11-28 UA UA2002075443A patent/UA75059C2/uk unknown
- 2000-11-28 HU HU0203597A patent/HU229458B1/hu unknown
- 2000-11-28 EE EEP200200283A patent/EE05305B1/xx unknown
- 2000-11-28 IL IL14957800A patent/IL149578A0/xx active IP Right Grant
- 2000-11-28 HK HK03100621.4A patent/HK1048445B/en not_active IP Right Cessation
- 2000-11-28 PL PL357597A patent/PL200679B1/pl unknown
- 2000-11-28 GB GB0214845A patent/GB2373726B/en not_active Expired - Lifetime
- 2000-11-28 ES ES00979765T patent/ES2236001T3/es not_active Expired - Lifetime
- 2000-11-28 NZ NZ518862A patent/NZ518862A/en not_active IP Right Cessation
- 2000-11-28 AT AT00979765T patent/ATE291914T1/de active
- 2000-11-28 AU AU17157/01A patent/AU778092B2/en not_active Expired
- 2000-11-28 EP EP00979765A patent/EP1237551B1/de not_active Expired - Lifetime
- 2000-11-28 WO PCT/GB2000/004528 patent/WO2001039772A1/en not_active Ceased
- 2000-11-28 DE DE60019162T patent/DE60019162T2/de not_active Expired - Lifetime
- 2000-11-28 HK HK03100515.3A patent/HK1048442B/zh not_active IP Right Cessation
- 2000-11-28 RU RU2002117649/15A patent/RU2255736C2/ru active
- 2000-11-28 CA CA002392050A patent/CA2392050C/en not_active Expired - Lifetime
- 2000-11-28 US US10/129,773 patent/US6750237B1/en not_active Expired - Lifetime
- 2000-11-28 CZ CZ20021901A patent/CZ301528B6/cs not_active IP Right Cessation
2002
- 2002-05-09 IL IL149578A patent/IL149578A/en unknown
- 2002-05-09 ZA ZA200203704A patent/ZA200203704B/xx unknown
- 2002-05-24 IS IS6394A patent/IS2135B/xx unknown
- 2002-05-28 NO NO20022525A patent/NO322119B1/no not_active IP Right Cessation
- 2002-05-29 MX MXPA02005319A patent/MXPA02005319A/es active IP Right Grant
2004
- 2004-05-27 US US10/854,959 patent/US7220767B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE60019162D1 (de)	2005-05-04
BR0016138A (pt)	2002-08-06
JP2003515559A (ja)	2003-05-07
US6750237B1 (en)	2004-06-15
CN1222287C (zh)	2005-10-12
PL200679B1 (pl)	2009-01-30
HK1048442A1 (en)	2003-04-04
HUP0203597A2 (hu)	2003-02-28
IL149578A0 (en)	2002-11-10
US7220767B2 (en)	2007-05-22
IL149578A (en)	2008-04-13
RU2255736C2 (ru)	2005-07-10
CA2392050C (en)	2009-11-24
DE60019162T2 (de)	2006-02-02
EE200200283A (et)	2003-06-16
GB9928578D0 (en)	2000-02-02
EP1237551B1 (de)	2005-03-30
HU229458B1 (en)	2013-12-30
UA75059C2 (uk)	2006-03-15
PT1237551E (pt)	2005-07-29
CA2392050A1 (en)	2001-06-07
CN1402636A (zh)	2003-03-12
EE05305B1 (et)	2010-06-15
ATE291914T1 (de)	2005-04-15
ES2236001T3 (es)	2005-07-16
CZ20021901A3 (cs)	2002-11-13
IS6394A (is)	2002-05-24
NZ518862A (en)	2004-02-27
NO20022525L (no)	2002-05-28
HK1053430A1 (en)	2003-10-24
HK1048442B (zh)	2005-05-13
GB2373726A (en)	2002-10-02
EP1237551A1 (de)	2002-09-11
HK1048445A1 (en)	2003-04-04
NO322119B1 (no)	2006-08-14
BRPI0016138B8 (pt)	2021-05-25
NO20022525D0 (no)	2002-05-28
AU1715701A (en)	2001-06-12
PL357597A1 (en)	2004-07-26
AU778092B2 (en)	2004-11-18
US20040214899A1 (en)	2004-10-28
CZ301528B6 (cs)	2010-04-07
KR100670092B1 (ko)	2007-01-17
SK287228B6 (sk)	2010-03-08
RU2002117649A (ru)	2004-01-27
HUP0203597A3 (en)	2005-07-28
GB2373726B (en)	2004-10-20
GB0214845D0 (en)	2002-08-07
BR0016138B1 (pt)	2013-09-10
KR20020058051A (ko)	2002-07-12
HK1048445B (en)	2005-08-26
MXPA02005319A (es)	2002-12-06
SK7532002A3 (en)	2002-12-03
IS2135B (is)	2006-08-15
WO2001039772A1 (en)	2001-06-07

Publication	Publication Date	Title
GB2373726B (en)	2004-10-20	Pharmaceutical formulations containing zolmitriptan
IL144294A0 (en)	2002-05-23	P53 inhibitors and therapeutic use of the same
GB0005251D0 (en)	2000-04-26	Therapeutic compounds
AU2003297260A1 (en)	2004-06-03	Fast-disintegrating solid dosage forms being not friable and comprising pullulan
YU37602A (sh)	2005-07-19	Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
MY129356A (en)	2007-03-30	Electrospun pharmaceutical compositions
MY115662A (en)	2003-08-30	Novel compounds with analgesic effect
MY132705A (en)	2007-10-31	Novel compounds with analgesic effect
GB0031088D0 (en)	2001-01-31	Medicaments
IS1907B (is)	2003-12-16	Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
IL153297A0 (en)	2003-07-06	Compounds and compositions for delivering active agents
TR200002773T2 (tr)	2001-11-21	Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
NO983555L (no)	1998-08-03	Ny formulering
SE9802208D0 (sv)	1998-06-22	Novel compounds
IL115589A0 (en)	1996-01-19	Use of cck-b antagonists in pharmaceutical compositions
IL141914A0 (en)	2002-03-10	Dosage form comprising liquid formulation
AU2001289606A1 (en)	2002-01-02	Dry powder formulation comprising racecadotril
WO2002039997A3 (en)	2002-11-28	Ace-2 modulating compounds and use thereof
PL348202A1 (en)	2002-05-06	Pharmaceutically active composition and dispensing device
SE0001916D0 (sv)	2000-05-23	Novel formulation
AP2000001950A0 (en)	2000-12-31	Paroxetine maleate.
MXPA01007952A (es)	2004-03-26	Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
ES2131482A1 (es)	1999-07-16	Formulacion acuosa de bambuterol.
BG104839A (en)	2001-09-28	Chrystalline form of paroxetine